Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease

Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease

Objective: Current evidence on the immunogenicity of influenza vaccination in patients with chronic obstructive pulmonary disease (COPD) is limited. To address this need for additional knowledge, we conducted a study on the immunogenicity of trivalent seasonal influenza vaccine (TIV) in COPD patient...

Full description

Bibliographic Details
Main Authors:	Yan Li, Ying Ma, Zhijie An, Chenyan Yue, Yamin Wang, Yunqiu Liu, Xiaodong Yuan, Shuping Zhang, Ming Shao, Changgui Li, Keli Li, Zundong Yin, Liye Wang, Huaqing Wang
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-09-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	immunogenicity safety trivalent seasonal influenza vaccine chronic obstructive pulmonary disease
Online Access:	http://dx.doi.org/10.1080/21645515.2021.1911515

Similar Items

A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam
by: Phan Trong Lan, et al.
Published: (2019-12-01)

Immunogenicity of a trivalent influenza vaccine and persistence of induced immunity in adults aged ≥60 years in Taizhou City, Zhejiang Province, China, during the 2018–2019 season
by: Yuting Liao, et al.
Published: (2022-11-01)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study
by: Yuemei Hu, et al.
Published: (2019-05-01)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
by: Zhaojun Mo, et al.
Published: (2017-06-01)

Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B
by: Xin Gong, et al.
Published: (2016-01-01)

Immunogenicity and safety of seasonal influenza vaccines in children under 3 years of age
by: Tia Aoun, et al.
Published: (2023-12-01)

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults
by: Goran Stevanovic, et al.
Published: (2018-03-01)

Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China
by: Yaping Chen, et al.
Published: (2022-12-01)

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®
by: Mathilde Latreille-Barbier, et al.
Published: (2017-11-01)

MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico
by: Aurelio Cruz-Valdez, et al.
Published: (2018-02-01)

Immunogenicity, Safety, and Efficacy of Influenza Vaccine in T2DM and T2DM with Chronic Kidney Disease
by: Henhen Heryaman, et al.
Published: (2024-02-01)

A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries
by: Margaret Haugh, et al.
Published: (2017-06-01)

Safety and Immunogenicity of Enterovirus 71 Vaccine (Vero Cell) Administered Simultaneously with Trivalent Split-Virion Influenza Vaccine in Infants Aged 6–7 Months: A Phase 4, Randomized, Controlled Trial
by: Yanhui Xiao, et al.
Published: (2023-04-01)

Immunogenicity and safety of a trivalent inactivated influenza vaccine
by: Eddy Fadlyana, et al.
Published: (2011-02-01)

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
by: Analia Urueña, et al.
Published: (2021-04-01)

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial
by: Shrikant Sharma, et al.
Published: (2018-06-01)

Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial
by: Robyn Hartvickson, et al.
Published: (2015-12-01)

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China
by: Shi-Yuan Wang, et al.
Published: (2017-11-01)

Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study
by: Renfeng Fan, et al.
Published: (2022-01-01)

Analysis of the adverse events following immunization with inactivated quadrivalent influenza vaccine from 2018 to 2020 in Zhejiang province, with a comparison to trivalent influenza vaccine
by: Huakun Lv, et al.
Published: (2021-11-01)

Evaluation of Pre-Pandemic Trivalent COBRA HA Vaccine in Mice Pre-Immune to Historical H1N1 and H3N2 Influenza Viruses
by: Pan Ge, et al.
Published: (2023-01-01)

Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 – 2018 season
by: Antonino Bella, et al.
Published: (2019-06-01)

Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach
by: Anita J. Brogan, et al.
Published: (2017-03-01)

Analysis of Viral and Host Factors on Immunogenicity of 2018, 2019, and 2020 Southern Hemisphere Seasonal Trivalent Inactivated Influenza Vaccine in Adults in Brazil
by: Artur Capão, et al.
Published: (2022-07-01)

Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy
by: Kei Nakashima, et al.
Published: (2017-03-01)

Trivalent inactivated influenza vaccine response and immunogenicity assessment after one week and three months in repeatedly vaccinated adults
by: Ahmed Tawfik, et al.
Published: (2023-12-01)

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy children (6 months to 17 years of age): a randomized, multicenter, phase III clinical trial
by: Sumantra Sarkar, et al.
Published: (2021-03-01)

Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis
by: Sandrine I. Samson, et al.
Published: (2019-03-01)

Factors influencing the immunogenicity of influenza vaccines
by: Simin Wen, et al.
Published: (2021-08-01)

Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence
by: Ilaria Loperto, et al.
Published: (2019-05-01)

Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis
by: Pablo Manuel Bianculli, et al.
Published: (2022-11-01)

Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model
by: Ming-Chin Yang, et al.
Published: (2017-01-01)

Protective efficacy of combined trivalent inactivated ISA 71 oil adjuvant vaccine against avian influenza virus subtypes (H9N2 and H5N1) and Newcastle disease virus
by: Zeinab Mohamed Ali, et al.
Published: (2017-10-01)

Factors affecting the immunogenicity of influenza vaccines in human
by: Qiuyi Xu, et al.
Published: (2023-04-01)

Immunogenicity and Clinical Efficacy of Influenza Vaccination In Pregnancy
by: Alexander W Kay, et al.
Published: (2015-06-01)

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay
by: Antonio Arbo, et al.
Published: (2022-11-01)

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response
by: Elena P. Mazunina, et al.
Published: (2024-04-01)

IMMUNOGENICITY OF ADJUVANT INFLUENZA VACCINE FOR PREGNANT WOMEN
by: M. P. Kostinov, et al.
Published: (2017-06-01)

Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review
by: Gael Dos Santos, et al.
Published: (2018-08-01)

INVESTIGATION OF TRIVALENT CHROMIUM-BASED CONVERSION COATINGS ON ELECTROGALVANISED STEEL
by: Célia Regina Tomachuk, et al.
Published: (2012-12-01)